Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) treatment has been approved by the Medicines and Healthcare ...

Many investors view the healthcare sector as a safe haven when the stock market is turbulent. Here are three no-brainer ...

UK MHRA approves Vertex’s Alyftrek, a once-daily next-in-class CFTR modulator to treat cystic fibrosis: London Monday, March 10, 2025, 10:00 Hrs [IST] Vertex Pharmaceuticals, a ...

The Nasdaq Composite Index ( ^IXIC -4.00%) is now squarely in correction territory. But stock market corrections have one key ...

Now squarely in 2025, we continue to extend our leadership in CF, notably with the recent approval and ongoing launch of ALYFTREK. We are continuing to build momentum with CASGEVY, our gene ...

There are hundreds of publicly traded companies on various equity markets worldwide. Investors choose to put their ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

The FDA gave a thumbs-up to the company's newest CF drug, Alyftrek, on Dec. 20, 2024. It approved Vertex's non-opioid drug Journavx for treating acute pain on Jan. 30, 2025. I fully expect both of ...